Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myelo ...
PDF (176 KB)
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Col ...
PDF (361 KB)
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Sma ...
PDF (298 KB)
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with ...
PDF (202 KB)
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
PDF (131 KB)
New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Mil ...
PDF (120 KB)
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with ...
PDF (180 KB)
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research I ...
PDF (157 KB)
Datopotamab Deruxtecan and ENHERTU® Show Promising Early Clinical Activity in Patients with Advance ...
PDF (326 KB)
​​​​​​​New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutate ...
PDF (215 KB)
Showing 1 - 10 of 44 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...